BTIG Maintains Buy on Zimmer Biomet Holdings, Lowers Price Target to $126
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Ryan Zimmerman maintains a Buy rating on Zimmer Biomet Holdings but lowers the price target from $134 to $126.
October 03, 2024 | 4:52 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BTIG analyst Ryan Zimmerman maintains a Buy rating on Zimmer Biomet Holdings but lowers the price target from $134 to $126, indicating a slightly less optimistic outlook.
The Buy rating suggests continued confidence in Zimmer Biomet's performance, but the lowered price target indicates a tempered outlook, which may lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100